Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in sales revenue and improvements in gross profit for Q3 2024, alongside increased operating expenses and a net loss attributable to common shareholders. Financial Highlights - Q3 2024 sales revenue increased 164% year-over-year to approximately $135 thousand from $51 thousand in Q3 2023 [3] - ARAKODA® pharmacy deliveries rose by 140% from 550 boxes in Q3 2023 to 1,319 boxes in Q3 2024 [3] - Gross profit improved to approximately $24 thousand in Q3 2024, compared to a gross loss of approximately $20 thousand in Q3 2023 [3] - Operating expenses were approximately $2.16 million in Q3 2024, up from approximately $1.58 million in Q3 2023 [3] - Net loss attributable to common shareholders was approximately $2.27 million, or ($0.93) per share, compared to a net income of approximately $4.09 million, or $9.13 per share in Q3 2023, representing a decline of $6.36 million [3] Business Highlights - The Company granted the University of Kentucky the right of reference to its NDA for ARAKODA®, facilitating FDA review of clinical efficacy and safety data [4] - A fixed-price contract was awarded to support commercial validation of new packaging for ARAKODA® by the United States Army Medical Materiel Development Activity [4] - Ethics approval was granted for an open label, expanded access study of ARAKODA® in immunosuppressed patients with persistent/relapsing babesiosis [4] - Clinical trial agreements were signed with all planned trial sites for the Tafenoquine Babesiosis Study [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for infectious diseases and achieved FDA approval for ARAKODA® in 2018 [5] - The Company collaborates with prominent research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private institutional investors [5]

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile. WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; S ...

60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria. This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied t ...

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma's regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company" or "60 Degrees Pharma" ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tickborne, potentially life-threatening illness Case studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunos ...

This has more than 12.5 million shares of SXTP stock being traded as of this writing. That's already well above its daily average trading volume of about 757,000 shares. The company's float is only 8.98 million units. What is worth keeping in mind is that SXTP is in penny stock territory. This comes from its low prior closing price of 25 cents and its market capitalization of just $3.003 million. Being a penny stock comes with certain vulnerabilities. That includes being open to volatility. This can happen ...

Company Overview - 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and focuses on developing and marketing new medicines for infectious diseases [1] - The company achieved FDA approval for its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 [1] - 60 Degrees Pharmaceuticals collaborates with prominent research organizations in the U.S., Australia, and Singapore [1] - The company is headquartered in Washington D.C. and has a majority-owned subsidiary in Australia [1] Product Information - ARAKODA® (tafenoquine) is approved for malaria prophylaxis in the U.S. and Australia, with commercial launches occurring in 2019 [6] - Tafenoquine has not been proven effective for the treatment or prevention of babesiosis and is not FDA-approved for this indication [8][11] Recent Developments - The company announced ethics approval for an open label, expanded access study of the ARAKODA® regimen in immunosuppressed patients with persistent/relapsing babesiosis [7] - The goal of the study is to confirm an 80% cure rate for babesiosis observed in a previous case series conducted by Yale School of Public Health [12] - The total accessible market for ARAKODA in babesiosis is estimated at 38,000 acute patients and at least 375,000 chronic patients in the U.S. [10] Clinical Trials - 60 Degrees Pharmaceuticals is advancing multiple clinical trials to establish the safety and efficacy of tafenoquine for babesiosis [14] - The trials include studies for hospitalized acute babesiosis patients, expanded access for persistent disease, and chronic babesiosis [15] - A New Drug Application with the FDA for a supplemental indication for tafenoquine in babesiosis is planned for the second quarter of 2026 [15]

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharmaceuticals" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis. Tafenoquine is approved for malaria prophylaxis in t ...